Navigation Links
ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial
Date:2/4/2008

Renowned cardiologists participate in controversial debate over effects of

Simvastatin vs. Ezetimibe/Simvastatin

CHICAGO, Feb. 4 /PRNewswire/ -- ReachMD, an innovative multi-channel platform for medical professionals, will air on XM Satellite Radio Channel 157 and simulcast via ReachMD Online at http://www.reachmd.com, a candid medical discussion on the much talked-about ENHANCE (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) Trial. Two of the nation's leading experts in Cardiology will share their insights over the only national broadcast network, created specifically for medical professionals.

Moderated by Dr. Matthew Sorrentino, associate professor of medicine at University of Chicago, this ReachMD Special Report will feature Dr. Steven Nissen, chairman of cardiology at the Cleveland Clinic, and Dr. Roger Blumenthal, head of preventive cardiology at Johns Hopkins University, who will for the first time openly debate among peers what this controversy means to the practicing physician and their patients.

The ENHANCE trial is a multinational, randomized, double-blind, trial that examines the effects of the highest approved dose of VYTORIN/INEGY versus the highest approved dose of simvastatin 80 mg alone in patients with Heterozygous Familial Hypercholesterolemia (HeFH). The study was made public by Merck/Schering-Plough Pharmaceuticals.

"The debate around the clinical study on cholesterol drugs has received heavy exposure in a short amount of time," said Gary Epstein, CEO of ReachMD. "However, there hasn't been a true, peer-to-peer discussion between the leading cardiologists in this type of setting. Our Special Report offers physicians an innovative platform to hear from medical experts in an environment created specifically for medical pro
'/>"/>

SOURCE ReachMD
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
4. Physicians Will Benefit from Medical Software Advice Website
5. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
6. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
7. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
8. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
9. Data Demonstrate that Obagi Medical Products Condition & Enhance Skin Care System is an Effective Complement to Facial Rejuvenation Procedures
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... 3 Stryker Corporation (...rectors has authorized the Company to repurchase u..., timing and amount of any purchases will be deter...valuation of market conditions, stock price and ot...iderations. Purchases may be made from time to ti...
(Date:12/3/2009)...Dec. 3 Decision Resources, one o...focusing on pharmaceutical and healthcare issues, ...Brazil will grow from $417 million in 2008 to $834...growth rate is attributed to a growing prevalent a...eneration antidiabetics such as Merck,s Januvia, N...
(Date:12/3/2009)...c. 3 Honeywell (NYSE: HON ) anno...th Pro-Lab Laboratuar Teknolojileri, which will di...igh-purity solvents in Turkey. ,, Burdick &...ology and pharmaceutical companies in the drug dis...rowth rate of the Turkish pharmaceutical market is...
Breaking Medicine Technology:Stryker Announces $750 Million Share Repurchase Program and Declares a $0.15 Per Share Quarterly Dividend 2Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 2Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 3Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 2Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 3Benji Marley or Bo 3A Three Genes Dictate Dogs Coat 55573 1Benji Marley or Bo 3A Three Genes Dictate Dogs Coat 55573 2Researchers identify new cancer causing role for protein 55569 1Researchers identify new cancer causing role for protein 55569 2Magid Abou Gharbia Ph D FRSC Joins LAXAI as Scientific Advisor 13725 1Magid Abou Gharbia Ph D FRSC Joins LAXAI as Scientific Advisor 13725 2Magid Abou Gharbia Ph D FRSC Joins LAXAI as Scientific Advisor 13725 3
...esearch, done in collaboration with the Centro de,... at the,University of Navarra, Pamplona, Spain, is...ress, Rotterdam, the Netherlands. , AMSTERDAM, the...herapeutics BV (AMT), a leader in the field of hum...ta on its AMT-020 gene therapy to,treat acute inte...
...OWN, N.Y.--(BUSINESS WIRE)--May 1, 2007 - Progenic...nced positive,results from the first clinical tria...uals infected with the human immunodeficiency,viru...eiving a,single 5.0 mg/kg dose of PRO 140 achieved...ns in the blood of 98.5% (1.83,log10), with indivi...
Other Medicine Technology:Amsterdam Molecular Therapeutics BV to present preclinical,proof-of-concept data on its gene therapy AMT-020 to treat acute,intermittent porphyria 2Amsterdam Molecular Therapeutics BV to present preclinical,proof-of-concept data on its gene therapy AMT-020 to treat acute,intermittent porphyria 3Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 2Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 3Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 4Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 5Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 6Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 7
(Date:12/3/2009)...ec. 3 The American Red ...ernational Brotherhood of Teamsters, Local 929 aft...ving the facility, interfering with blood shipment...wscom.com/cgi-bin/prnh/20081216/DC52619LOGO ) ,... the American Red Cross Blood Services Penn-Jersey...
(Date:12/3/2009)...., Dec. 3 The Cancer Center at H... patients, Harrington Hospital announced today. ,...y," said Diane Becquart, Director of The Cancer Ce... today by the Massachusetts Department of Public H... facility. ,, The opening of The Cancer Center...
(Date:12/3/2009)...c. 3 /PRNewswire-Asia/ -- Long believed to provide...most important ingredients in global,cuisine, has ...son. , The timing of this ginger demand i... upward price pressures in a way that has speculat...ent demand hysteria over garlic. Garlic, also,beli...
(Date:12/3/2009)..., Md., Dec. 3 We are closer than e...ensures affordable, quality care for all. The Ame...ntact their representatives and voice their suppor...eo from ANA at: http://inr.mediaseed.tv/ANA_37124...system that focuses on wellness and prevention, a ...
(Date:12/3/2009)...ften play out at school and home, study finds , ...ool bullies are also likely to bully their brother...dy that included 195 children between the ages of ...ling no more than four years older or younger than...ullied at school or at home. The findings were pub...
Breaking Medicine News(10 mins):Health News:American Red Cross Wins Court Injunction Against Striking Teamsters 2Health News:Cancer Center at Harrington to Begin Seeing Patients 2Health News:Cancer Center at Harrington to Begin Seeing Patients 3Health News:Ginger Prices Could Skyrocket on H1N1 Fears 2Health News:VIDEO from Medialink and the American Nurses Association (ANA): American Nurses Association Urges All Americans to Take Part in Health Care Reform Debate 2Health News:Bullies May Intimidate Siblings, Too 2
... for Cancer Research (LICR) announced today that o...euticals, has licensed its lead cancer therapy can...bott. , The 806 antibody targets the EGFR cell s...me types of cancers. Current therapies that target...
...rticipants gathered this week for the sixth annual...ence. This year,s topic, "Complex Systems," drew s...sts, and philosophers to discuss new interdiscipli..., director, Center for Polymer Studies, Boston Uni...
...warns consumers about cosmetic injection discounts...008 -- Bargains on consumer goods and services may...ic times, however when related to cosmetic injecti...gain prices, deep discounts or purported sales on ...
...s report promising results for the viability of a ...t technique that may enhance the differential diag...tissue and normal skin in vivo. Recently publishe... and Surgery, the retrospective study discussed th...
...er patients who participate in intervention sessio... and altering health behaviors live longer than pa...rt. Published in the December 15, 2008 issue of C...reatment can have a significant impact on patients...
... DFMO may influence the extent of Barrett,s dyspla...study of this agent in a larger number of patients...sor of medicine and oncology at the Mayo Clinic, R...ontiers in Cancer Prevention Research. , The sin...
Other Medicine News:Health News:Conference on complexity offers new opportunities for interdisciplinary collaboration 2Health News:Beware Botox Bargains in Tough Economic Times 2Health News:Beware Botox Bargains in Tough Economic Times 3Health News:Beware Botox Bargains in Tough Economic Times 4Health News:Future Looks Bright For Non-Invasive Diagnosis Of Skin Cancer; Study Shows Novel Light Device Detects Cancerous Lesions From Normal Tissue 2Health News:Future Looks Bright For Non-Invasive Diagnosis Of Skin Cancer; Study Shows Novel Light Device Detects Cancerous Lesions From Normal Tissue 3Health News:Psychological interventions associated with breast cancer survival 2Health News:DFMO may affect Barrett's esophagus 2
Beaupre Cilia Forceps
Ehrhardt Lid Forceps
Snellen Entropion Forceps - Small - Right
Francis Chalazion Forceps
Medicine Products: